Clinical trials
Therapy clinical trials
Below are recruiting therapy clinical trials, each written for real people, not researchers. We’re tracking 7,182 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07247825Recruiting
Needle treatment for shoulder tendon pain: single vs multi-filament
This study tests two types of a needle-based treatment (percutaneous electrolysis) for shoulder tendon pain. It aims to see if a single-filament or multi-filament approach works better for people with chronic supraspinatus tendon issues.
SalamancaAges 18–65 - NCT07242352RecruitingPhase 3
Comparing elacestrant to standard hormone therapy for high-risk early breast cancer
This trial tests a new hormone therapy drug called elacestrant against standard hormone treatments for people with a specific type of early breast cancer (ER+/HER2-) that has a high chance of coming back. The goal is to see if elacestrant works better at keeping the cancer from returning.
Mannheim, Baden-WurttembergAges 18 years+ - NCT07244445Recruiting
Pistachios with GLP-1 therapy for weight and nutrition
This study tests whether adding pistachios to your diet can improve nutrition and weight loss while you are already on a GLP-1 medication like Wegovy, Ozempic, or Mounjaro. It is open to adults who have been on the medication for at least three months.
Clevland, OhioAges 18–80 - NCT07246668RecruitingPhase 2
Carbon ion radiation with immunotherapy for advanced liver cancer
This trial tests a combination of carbon ion radiation therapy with two drugs, atezolizumab and bevacizumab, for people with advanced liver cancer that cannot be surgically removed. The goal is to see if this approach is safe and effective.
SeoulAges 20 years+ - NCT07246278RecruitingPhase 1/Phase 2
Celecoxib for Parkinson's: A new way to treat symptoms
This trial tests if adding celecoxib, an anti-inflammatory drug, to standard Parkinson's treatment can help improve symptoms. If you have Parkinson's disease and are at least 18, this study might be an option for you.
TantaAges 50–80 - NCT07247396RecruitingPhase 1
CEA CAR-T therapy after surgery for colorectal cancer spread
This trial tests a special immune cell therapy (CAR-T) that targets a protein called CEA on cancer cells. It is for people with colorectal cancer that has spread to the lining of the belly (peritoneum) and who have already had surgery to remove as much of the spread as possible.
Hangzhou, ZhejiangAges 18–75 - NCT07242222RecruitingPhase 1/Phase 2
Erdosteine for non-alcoholic fatty liver disease
This trial tests whether a medicine called erdosteine can help treat non-alcoholic fatty liver disease (a condition where extra fat builds up in the liver, not caused by alcohol). It is for adults who have fatty liver confirmed by ultrasound and who do not have other serious health problems.
TantaAges 18–60 - NCT07243704RecruitingPhase 3
Antiplatelet medicine to prevent heart events after brain bleed
This trial tests whether a common antiplatelet medicine can reduce the risk of future heart attacks, strokes, or blood clots in people who have had a brain bleed. It's for adults who had their first brain bleed and can start treatment within 3 months of the stroke.
Guntur, Andhra PradeshAges 18–99 - NCT07246707RecruitingPhase 1
KSV01 injection for relapsed or refractory B-cell acute lymphoblastic leukemia
This trial tests an investigational drug called KSV01 for people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back or hasn't responded to standard treatments. It aims to see if the drug can help control the cancer.
HangzhouAges 18–80 - NCT07241728Recruiting
Bruxism and electrical current for jaw pain relief
This study tests whether a type of mild electrical current (called diadinamic current) can help relieve jaw pain caused by bruxism (teeth grinding or clenching). It is for adults who have not tried other treatments for this pain.
MalatyaAges 18 years+ - NCT06296979Recruiting
Nerve stimulation for shoulder pain from liver or gallbladder issues
This study tests if stimulating a nerve in the neck can reduce right shoulder pain caused by liver or gallbladder problems. It may offer a non-drug option for managing this type of pain.
Seville, SevillaAges 18 years+ - NCT06414720Recruiting
Saliva microRNA test for endometriosis on progestin therapy
This study looks at small molecules in saliva called microRNAs to see if they can help predict how well endometriosis responds to hormone therapy. It may help doctors choose the best treatment for you.
Udine, UDAges 18–45 - NCT06620848RecruitingPhase 2
A trial of HRS-4642 alone or with adebrelimab for advanced bile duct cancer
This trial tests a new drug, HRS-4642, either by itself or combined with another drug called adebrelimab, for people whose advanced bile duct cancer has come back or gotten worse after standard treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06852209Recruiting
Brain training with neurofeedback after a stroke
This study tests a brain-training technique called neurofeedback to see if it can improve thinking skills after a stroke. If you have ongoing memory or attention problems despite recovery, this trial may help you train your brain using real-time feedback from your own brain activity.
BordeauxAges 18–75 - NCT04462042Recruiting
Proton vs photon radiation for anal canal cancer
This study compares two types of radiation—protons versus photons—for anal canal squamous cell carcinoma. It may help find which option delivers treatment more effectively or with fewer side effects.
GothenburgAges 18 years+ - NCT07235176RecruitingPhase 1/Phase 2
QLS1304 plus hormone therapy for ER+ breast cancer
This trial tests a new drug called QLS1304 combined with hormone therapy for people with ER-positive, HER2-negative breast cancer that has spread or come back and no longer responds to hormone therapy alone. The goal is to see if this combination can help shrink tumors or slow the disease.
ShanghaiAges 18 years+ - NCT07239323RecruitingPhase 1
CAR-T therapy for blood cancers that have returned or not responded
This trial tests a new CAR-T cell therapy for people with certain blood cancers (B-cell acute lymphoblastic leukemia, B-cell lymphoma, or multiple myeloma) that have come back or stopped responding to treatment. The therapy uses your own immune cells, modified in a lab to attack cancer cells, then given back to you intravenously.
Kunming, YunnanAges 18 years+ - NCT07232849RecruitingPhase 2
New drug combo for advanced lung cancer
This trial tests a new drug, HRS-4508, given with other cancer treatments for people with advanced non-small cell lung cancer whose previous treatments have failed. The goal is to see if this combination can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07231445RecruitingPhase 1
ZG006 with immunotherapy for extensive small cell lung cancer
This trial tests a new drug, ZG006, combined with standard immunotherapy (PD-1/PD-L1 inhibitors) for people with advanced small cell lung cancer that hasn't been treated before. The goal is to find out if this combination works better than the current standard care.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07235202RecruitingPhase 1/Phase 2
MR001 plus chemo for advanced pancreatic cancer after first treatment
This trial tests a new drug, MR001, combined with chemotherapy for people whose pancreatic cancer has spread and no longer responds to their first treatment. It aims to see if this combination can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT07237009Recruiting
Personalized reminiscence therapy for memory loss
This trial tests a digital app that uses personal photos and memories to help people with early memory problems feel less depressed or apathetic. It's designed for seniors who have mild cognitive impairment or early dementia.
AngersAges 60 years+ - NCT07236801RecruitingPhase 1
Cell therapy for hard-to-treat autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with several autoimmune diseases that have not improved with standard medications. It aims to see if this treatment can help control the disease when other treatments have failed.
Xuzhou, JiangsuAges 18–65 - NCT07232875RecruitingPhase 3
New drug combo for first-line advanced pancreatic cancer
This trial tests a new drug (HRS-4642) combined with standard chemotherapy as a first treatment for advanced pancreatic cancer that has spread. It may help shrink tumors and extend life.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07231458RecruitingPhase 1
Testing a new immunotherapy with pembrolizumab for advanced solid tumors
This trial tests ABX-001, a new immunotherapy, alone or with pembrolizumab, for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. It may help if your tumor has become resistant to previous immunotherapies.
BerlinAges 18 years+
Hear when a new Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for therapy?
- Yes. Clin2 currently lists 7,182 recruiting therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.